Benitec Biopharma Inc. has switched its accountant from Baker Tilly to Ernst & Young.

Sep 24, 2026, 4:56 PM ETPaperworkRead the original at sec.gov

Neutral

Benitec appointed Ernst & Young after a governance review, and its previously reported control weakness was remediated; the auditor change and pending acceptance leave the company view unchanged.

BNTC · Benitec Biopharma Inc.

AI read · Neutral

The AI's read

Switching to a Big Four auditor is a governance signal but not a finished event. Baker Tilly's prior audit opinions were clean and the reported control weakness was fixed, so positives and procedural uncertainty balance.

Get alerts for BNTC

Follow Benitec Biopharma Inc. (BNTC) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BNTC

Free on the App Store and Google Play, or on the web.